Mark Murphy Email

VP, Finance . REGENXBIO

Current Roles

Employees:
410
Revenue:
$93.1M
About
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and thirdparty NAV Technology Platform licensees.
REGENXBIO Address
9804 Medical Center Drive
Rockville, MD
United States
REGENXBIO Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.